Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
Monday, December 4, 2023 BiopharmaWatch Research 1 min read
Key Takeaway: Precision BioSciences has announced a publication in Nature Metabolism that supports the use of its ARCUS gene editing technology as a potentially curative treatment for mitochondrial diseases. The study highlights ARCUS's ability to specifically target and eliminate mutant m.3243G mitochondrial DNA, demonstrating efficient shifting of heteroplasmy without off-target effects. This advancement could significantly impact treatment options for patients with mitochondrial disorders.
Price reaction · baseline $10.95 (2023-12-01 close) · hit pre-market · clean, no other DTIL news in the window
Demonstrated high specificity without off-target activity.
Potentially curative treatment for mitochondrial diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Publication validates unique ability of ARCUS genome editing to preferentially target and eliminate mutant m.3243G mitochondrial DNA (mtDNA) with high specificity – mitoARCUS efficiently shifted m.3243A>G heteroplasmy without off-target activity, leading to an overall improvement in mitochondrial
Frequently Asked Questions
What is ARCUS gene editing?
ARCUS gene editing is a technology developed by Precision BioSciences that targets and modifies specific DNA sequences.
What diseases could ARCUS potentially treat?
ARCUS has shown potential as a curative treatment for mitochondrial diseases.
What did the Nature Metabolism publication validate?
The publication validated ARCUS's ability to specifically target and eliminate mutant mitochondrial DNA.
Does ARCUS have off-target effects?
ARCUS demonstrated high specificity without off-target activity in the study.